Drug Trial Radar · NCT05593666
A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis
Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Dec 27, 2022
Primary completion
Apr 15, 2025
Study completion Dec 22, 2025
Sponsor
- Lead sponsor
- Drugs for Neglected DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis Pharmaceuticals
- First posted
- Oct 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, multicentre, randomized, two-arm blinded study with an open label calibrator arm in adults and adolescents (≥12 years) with confirmed primary VL.
Conditions
- Primary Visceral Leishmaniasis
Interventions
LXE408Drug
Film-coated tablets
PlaceboOther
Placebo film-coated tablets
AmBisome®Drug
Sterile lyophilised powder in a 15 mL sterile clear glass vial
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with initial cure at Day 28 for LXE408Time frame: Day 28
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
DrugsNeglectedD Investigational Site
Bihār, India
DrugsNeglectedD Investigational Site
Patna, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.